How to Read Your HRT Lab Results

Educational only. Not medical advice. Lab results should be interpreted by your clinician in the context of your full clinical picture. A single lab value out of range does not necessarily mean your treatment needs to change. Do not adjust your HRT based on lab results without clinician guidance.

Your clinician orders labs. Results arrive in your patient portal. You open them and see numbers, ranges, and flags you do not fully understand. You Google “high FSH” and end up more confused than before.

Lab results are a tool, not a verdict. They are one piece of a clinical picture that includes your symptoms, your history, your current regimen, and how you feel. Understanding what each marker measures and what the numbers mean in the context of HRT helps you have a more productive conversation with your clinician - and prevents unnecessary anxiety over results that are expected and normal during treatment.

• Clinical response (how you feel) is the primary measure of HRT adequacy, not a specific lab number
• Estradiol levels on HRT vary by route: oral produces higher peaks and troughs, transdermal produces more stable levels, and topical absorption is variable
• FSH drops on adequate HRT but does not need to reach any specific target
• A lipid panel is important because oral estrogen can raise triglycerides
• Liver function tests are relevant for oral estrogen users and mandatory for fezolinetant
• “Out of range” does not always mean “problem.” Some shifts are expected on HRT

Estradiol (E2). What it measures: the primary estrogen in your body and the hormone you are replacing with HRT. What you want to see: for menopausal symptom control, Some clinicians reference a range of approximately 40 to 100 pg/mL for symptom relief, but there is no universally agreed-upon target. Major guidelines including IMS and ACOG state that serum estradiol levels should generally not be used to determine HRT dosing - symptom response is the primary guide. Checking estradiol levels may be useful in specific troubleshooting scenarios: persistent symptoms despite adequate-seeming doses, unexplained breakthrough bleeding, or when switching between formulations. Routine monitoring of estradiol levels is not standard practice for most women on HRT

Route matters for interpretation. Oral estradiol produces a peak 4 to 8 hours after dosing and a trough before the next dose - timing of the blood draw relative to your dose affects the result. Transdermal (patch) produces more stable levels. It is less affected by draw timing but still varies with patch age (higher after application, lower before change day). Topical (gel/spray) has the most variable absorption. Levels can differ significantly between individuals and even between draws in the same individual.

Practical note: if your symptoms are well-controlled, a “low” estradiol level does not mean you need more. And if your symptoms persist despite a “good” level, you may need adjustment regardless of the number. Symptoms guide treatment. Labs confirm.

FSH (Follicle-Stimulating Hormone). What it measures: the pituitary hormone that rises as ovarian function declines. Pre-menopause: typically below 10 mIU/mL. Perimenopause: fluctuates wildly (10 to 100+ mIU/mL). Postmenopause without HRT: typically above 30 to 40 mIU/mL. On adequate HRT: FSH drops because the exogenous estrogen provides negative feedback to the pituitary. It does not need to reach a specific target.

When it is useful: confirming menopause in women under 45 (if consistently elevated above 30 to 40 on multiple draws). FSH levels are useful for confirming menopause status in ambiguous cases (such as women who started HRT before periods fully stopped, or women who had a hysterectomy without oophorectomy). However, FSH should not be used to monitor HRT dose adequacy or to titrate therapy. Major guidelines including EMAS state that FSH levels should not be used to guide HRT dosing - symptom response is the appropriate measure. When it is not useful: single draws during perimenopause (too variable to interpret).

Progesterone. What it measures: progesterone levels, relevant for women on progestogen therapy. When checked: occasionally during cyclic regimens to confirm adequate levels during the progestogen phase, or when compliance is a question. Not routinely monitored in most HRT protocols because clinical endpoints (endometrial protection, breakthrough bleeding patterns) are more useful than the number itself.

Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides). Why it matters for HRT: oral estrogen can increase triglycerides through first-pass liver metabolism. This is clinically relevant for women with already-elevated triglycerides. Transdermal estrogen has less triglyceride effect because it bypasses the liver. Oral estrogen tends to increase HDL (favorable) and may modestly decrease LDL. These lipid effects are route-specific and should be tracked.

Baseline lipids before starting HRT and repeat at 6 to 12 months is standard practice. If triglycerides rise significantly on oral estrogen, a switch to transdermal may be warranted.

Complete Metabolic Panel (CMP). Includes liver function tests (AST, ALT), kidney function (creatinine, BUN), electrolytes, and glucose. Why it matters: liver function is relevant for oral estrogen users (first-pass hepatic metabolism). Fasting glucose and metabolic markers help track the insulin resistance changes that occur during menopause. Kidney function affects medication clearance.

Thyroid Panel (TSH, sometimes Free T4). Why it is included at baseline: hypothyroidism symptoms overlap extensively with menopausal symptoms. Diagnosing and treating thyroid disease appropriately prevents misattribution of symptoms to menopause. A TSH within normal range (approximately 0.4 to 4.0 mIU/L, depending on the lab) rules out significant thyroid dysfunction. TSH does not need to be “optimized” beyond the normal range for women on HRT.

CBC (Complete Blood Count). Why it is included: screens for anemia (which causes fatigue that mimics menopause), particularly relevant for perimenopausal women with heavy bleeding. Not typically affected by HRT at standard doses.

Vitamin D. Often included in baseline panels. Relevant for bone health - deficiency is common and should be corrected, particularly for women on HRT for osteoporosis prevention. Target: generally above 30 ng/mL, with some guidelines recommending 40-60 ng/mL for bone health.

All flags green, symptoms controlled. Continue current regimen. Repeat labs per your clinician’s monitoring schedule (typically annually for stable patients).

Estradiol low, symptoms persist. Likely underdosed or poor absorption. Discuss dose increase or route change. Recheck in 4 to 6 weeks after adjustment.

Estradiol adequate, symptoms persist. The problem may not be estrogen levels. Evaluate for other contributors (sleep apnea, thyroid, depression, medication side effects). Consider add-on therapy or route change.

Triglycerides elevated. If on oral estrogen, consider switching to transdermal. Evaluate dietary factors. Recheck in 3 months.

Liver enzymes elevated. If on oral estrogen, evaluate for other causes. Consider switching to transdermal (bypasses liver). If on fezolinetant, this is a monitored side effect - follow FDA-required monitoring schedule.

TSH out of range. Evaluate and treat thyroid disease independently. Do not attribute thyroid symptoms to menopause or vice versa.

• What labs do you recommend at baseline, and what is the follow-up schedule?
• My estradiol is [number] - is that adequate for my route and dose?
• Should I time my blood draw relative to my dose (for oral) or patch change (for transdermal)?
• My triglycerides increased since starting HRT - should we switch routes?
• Do I need any additional testing based on my risk factors?